Loading clinical trials...
Loading clinical trials...
A long-term follow-up study to assess safety and efficacy in patients previously treated with Mustang Bio chimeric antigen receptor (CAR)-T cell investigational products.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Mustang Bio
NCT06006403 · Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), and more
NCT04013685 · Acute Myeloid Leukemia, Acute Lymphoid Leukemia, and more
NCT07007052 · Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
NCT02113982 · Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Acute Myeloid Leukemia (AML)
NCT03599960 · Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
UC Irvine Health - Chao Family Comprehensive Cancer Center
Orange, California
Massachusetts General Hospital
Boston, Massachusetts
University of Rochester Medical Center
Rochester, New York
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions